Uwm Research Foundation, Inc.

Wisconsin Alumni Research Foundation

Wisys Technology Foundation, Inc.

Ojas A Namjoshi

James M Cook

Michael Ming-Jin Poe

Hiteshkumar D Jain

Shengming Huang

Sundari K Rallipalli

Zhi-jian Wang

Yun Teng Johnson

Terry S Clayton

Jie Yang

Jianming Yu

Qi Huang

Xiaohui He

Dongmei Han

Rahul Edwankar

Xiaoyan Li

Zhi-Jian Wang

In preferred embodiments, the present invention provides methods of treatment and pharmaceutical compositions for the suppression, alleviation and prevention of the often chronic, severe and debilitating pain that can accompany inflammatory diseases and neuropathic insults, pain that is often unresponsive to conventional analgesic treatment. The preferred embodiments of the present invention further relate to methods of treatment and pharmaceutical compositions using benzodiazepine derivatives that provide suppression, alleviation and prevention of neuropathic pain, migraine-related pain and inflammatory pain with reduced sedative and ataxic side effects.

Selective agents for pain suppression

Described herein are &#x3b1;3 or &#x3b1;2 or &#x3b1;2/&#x3b1;3 GABAergic receptor subtype selective ligands, pharmaceutical compositions, and methods of use of such ligands and compositions in treatment of anxiety disorders, epilepsy and schizophrenia with reduced sedative and ataxic side effects. In embodiments, such as &#x3b1;3 or &#x3b1;2 or &#x3b1;2/&#x3b1;3 GABAergic receptor subtype selective ligands lack ester linkages and may be thus relatively insensitive to hydrolysis by esterases.

GABAergic receptor subtype selective ligands and their uses

Gabaergic receptor subtype selective ligands and their uses

Growing community of inventors

Cary, NC, United States of America

Ojas A Namjoshi